Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 10:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Primary Generalized Tonic-Clonic Seizures Clear all

Completed Phase 3 Interventional Results available

Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures

NCT00104416

View directory record Official record

Conditions: Epilepsy, Tonic-Clonic
Interventions: lamotrigine (LAMICTAL) extended-release, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 13 Years and older

Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 64
States / cities: Anniston, Alabama • Birmingham, Alabama • Northport, Alabama + 56 more

Source: ClinicalTrials.gov public record

Updated Jan 1, 2017 · Synced May 21, 2026, 10:12 PM EDT

Completed Phase 3 Interventional Results available

Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

NCT02849626

View directory record Official record

Conditions: Partial-Onset or Primary Generalized Tonic-Clonic Seizures
Interventions: Perampanel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 4 Years to 12 Years

Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 29
States / cities: Little Rock, Arkansas • Palo Alto, California • Aurora, Colorado + 25 more

Source: ClinicalTrials.gov public record

Updated Oct 27, 2022 · Synced May 21, 2026, 10:12 PM EDT

Completed Phase 4 Interventional

Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug

NCT00043901

View directory record Official record

Conditions: Epilepsy, Tonic-Clonic
Interventions: lamotrigine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 2 Years and older

Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 80
States / cities: Alabaster, Alabama • Mobile, Alabama • Northport, Alabama + 71 more

Source: ClinicalTrials.gov public record

Updated Apr 3, 2017 · Synced May 21, 2026, 10:12 PM EDT

Active, not recruiting Phase 3 Interventional

RNS System NAUTILUS Study

NCT05147571

View directory record Official record

Conditions: Epilepsy, Idiopathic Generalized Epilepsy, Generalized Tonic Clonic Seizure
Interventions: Responsive stimulation, Sham stimulation; Device
Lead sponsor: NeuroPace; Industry
Eligibility: 12 Years and older

Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 18 more

Source: ClinicalTrials.gov public record

Updated Jul 8, 2025 · Synced May 21, 2026, 10:12 PM EDT

Recruiting Phase 2 Interventional

An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures

NCT06908356

View directory record Official record

Conditions: Focal Onset Seizure, Primary Generalized Epilepsy
Interventions: 30mg PRAX-628; Drug
Lead sponsor: Praxis Precision Medicines; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 8
States / cities: Phoenix, Arizona • Miami Lakes, Florida • Bethesda, Maryland + 5 more

Source: ClinicalTrials.gov public record

Updated Apr 2, 2025 · Synced May 21, 2026, 10:12 PM EDT

Completed Phase 2 Interventional Results available

Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

NCT01118949

View directory record Official record

Conditions: Epilepsy
Interventions: Lacosamide; Drug
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 16 Years to 65 Years

Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 25
States / cities: Alabaster, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more

Source: ClinicalTrials.gov public record

Updated Jul 16, 2018 · Synced May 21, 2026, 10:12 PM EDT

Completed Phase 3 Interventional Results available

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

NCT02408523

View directory record Official record

Conditions: Epilepsy
Interventions: Lacosamide Tablet, Lasosamide Oral Solution, Placebo Tablet, Placebo Oral Solution; Drug · Other
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 4 Years and older

Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 27
States / cities: Alabaster, Alabama • Little Rock, Arkansas • Irvine, California + 23 more

Source: ClinicalTrials.gov public record

Updated Dec 16, 2020 · Synced May 21, 2026, 10:12 PM EDT

Enrolling by invitation Phase 3 Interventional

Clinical Trial of Vormatrigine in Adult Patients With Epilepsy

NCT07287163

View directory record Official record

Conditions: Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure
Interventions: vormatrogine; Drug
Lead sponsor: Praxis Precision Medicines; Industry
Eligibility: 18 Years to 85 Years

Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Miami Lakes, Florida • Naples, Florida • Lafayette, Louisiana + 6 more

Source: ClinicalTrials.gov public record

Updated Dec 16, 2025 · Synced May 21, 2026, 10:12 PM EDT

Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

NCT03288129

View directory record Official record

Conditions: Partial Onset Seizures, Secondarily Generalized Seizures, Primary Generalized Tonic-Clonic Seizures
Interventions: Perampanel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 4 Years and older

Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 20 more

Source: ClinicalTrials.gov public record

Updated May 15, 2022 · Synced May 21, 2026, 10:12 PM EDT

Completed Phase 3 Interventional Results available

A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

NCT01463306

View directory record Official record

Conditions: Epilepsy, Partial Seizures, Epilepsy, Primary Generalized Tonic-Clonic Seizures
Interventions: Pregabalin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 1 Month to 66 Years

Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 21
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more

Source: ClinicalTrials.gov public record

Updated Jan 19, 2021 · Synced May 21, 2026, 10:12 PM EDT

Completed Phase 3 Interventional Results available

Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures

NCT02408549

View directory record Official record

Conditions: Epilepsy
Interventions: Lacosamide Tablet, Lacosamide Oral Solution; Drug
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 4 Years and older

Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 16
States / cities: Little Rock, Arkansas • Santa Monica, California • Colorado Springs, Colorado + 13 more

Source: ClinicalTrials.gov public record

Updated Dec 13, 2023 · Synced May 21, 2026, 10:12 PM EDT

Completed Phase 2 Interventional Results available

Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

NCT01118962

View directory record Official record

Conditions: Epilepsy
Interventions: Lacosamide; Drug
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 16 Years to 65 Years

Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 19
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 16 more

Source: ClinicalTrials.gov public record

Updated Jul 16, 2018 · Synced May 21, 2026, 10:12 PM EDT

Recruiting Phase 3 Interventional

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

NCT05667142

View directory record Official record

Conditions: Primary Generalized Tonic-Clonic Seizures
Interventions: XEN1101, Placebo; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 12 Years and older

Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 59
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more

Source: ClinicalTrials.gov public record

Updated May 14, 2026 · Synced May 21, 2026, 10:12 PM EDT

Completed Phase 3 Interventional

Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

NCT03678753

View directory record Official record

Conditions: Primary Generalized Epilepsy
Interventions: Cenobamate, Placebo; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 12 Years and older

Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 43
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 37 more

Source: ClinicalTrials.gov public record

Updated Jul 8, 2025 · Synced May 21, 2026, 10:12 PM EDT

Completed Phase 3 Interventional Results available

A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.

NCT01747915

View directory record Official record

Conditions: Generalized Tonic Clonic Seizures
Interventions: Pregabalin Dose Level 1, Pregabalin Dose Level 2, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 5 Years to 65 Years

Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 12
States / cities: Loxahatchee Groves, Florida • Orlando, Florida • Port Charlotte, Florida + 6 more

Source: ClinicalTrials.gov public record

Updated Jan 19, 2021 · Synced May 21, 2026, 10:12 PM EDT

Recruiting Phase 2 Interventional

Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases

NCT07130786

View directory record Official record

Conditions: Seizures, Primary Motor Cortex, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Adult, Brain Metastases From Extra-cranial Solid Tumors
Interventions: Levetiracetam (Keppra); Drug
Lead sponsor: Ayal A. Aizer, MD; Other
Eligibility: 18 Years and older

Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Mar 18, 2026 · Synced May 21, 2026, 10:12 PM EDT

Enrolling by invitation Phase 3 Interventional

Cenobamate Open-Label Extension Study for YKP3089C025

NCT03961568

View directory record Official record

Conditions: Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy
Interventions: Cenobamate; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 12 Years and older

Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 16
States / cities: La Jolla, California • Miami, Florida • Tampa, Florida + 13 more

Source: ClinicalTrials.gov public record

Updated Jan 6, 2026 · Synced May 21, 2026, 10:12 PM EDT